Cetuximab and the Head and Neck Squamous Cell Cancer

Riccardo Concu; M Natalia D S Cordeiro

doi:10.2174/1568026618666180112162412

Cetuximab and the Head and Neck Squamous Cell Cancer

Curr Top Med Chem. 2018;18(3):192-198. doi: 10.2174/1568026618666180112162412.

Authors

Riccardo Concu¹, M Natalia D S Cordeiro¹

Affiliation

¹ REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal.

PMID: 29332581
DOI: 10.2174/1568026618666180112162412

Abstract

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.

Keywords: Cancer; Cell; Cetuximab; Cytotoxic T lymphocytes; Epidermal growth factors; Food and Drug Association..

Publication types

Review

MeSH terms

Antineoplastic Agents / chemistry
Antineoplastic Agents / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Cetuximab / chemistry
Cetuximab / therapeutic use*
Drug Screening Assays, Antitumor
Head and Neck Neoplasms / drug therapy*
Humans
Structure-Activity Relationship

Substances

Antineoplastic Agents
Cetuximab